Allogenic Stem Cell Transplantation from Alfabeta T/Cd19 Depleted Haploidentical Donor as Salvage Therapy in In Heavily Pretreated Relapsed/Refractory Patients with Hodgkin Lymphoma

For decades, the medical community has faced a difficult reality with Hodgkin lymphoma, a cancer of the immune system. While modern treatments like chemotherapy, radiation, and new immunotherapy drugs can often put the disease into remission, a stubborn minority of patients eventually see the cancer return or refuse to go away. For these individuals, the only remaining path to a potential cure has been a procedure called an allogeneic stem cell transplant. This involves replacing a patient's entire bone marrow with healthy cells from a donor, hoping the new immune system will recognize and destroy any remaining cancer cells. However, this life-saving procedure carries a heavy price. The new immune system often attacks the patient's body in a violent reaction known as graft-versus-host disease, while the intense preparation required to clear out the old marrow leaves the patient vulnerable to severe infections. For many, the treatment itself becomes more dangerous than the disease.

Researchers at the University of Parma in Italy have been exploring a way to keep the curative power of this transplant while removing the most dangerous side effects. They focused on a specific type of donor: a family member who is not a perfect genetic match, known as a haploidentical donor. Because perfect matches are rare and hard to find quickly, using a family member offers a faster, more accessible option. The challenge has always been that these mismatched donors carry a higher risk of the new immune system attacking the host. To solve this, the team developed a method to carefully filter the donor's cells before they are given to the patient. They removed the specific immune cells that cause the dangerous attacks, while keeping other cells that help fight infection and cancer. This study, which followed patients over many years, suggests that this filtered approach can offer a safe and effective cure for patients who have run out of other options.

The team at the University of Parma treated a group of eleven adults who had relapsed or had Hodgkin lymphoma that did not respond to standard treatments. These patients were heavily treated, having undergone an average of five different lines of therapy before arriving at this point. Many had already tried their own stem cell transplant, and some had even received drugs that block the immune system's checkpoints, which are now common in cancer care. Because these patients had exhausted other options, the doctors turned to a transplant from a close family member, such as a parent, sibling, or child. The critical step in this process happened before the transplant began. The doctors took the donor's blood stem cells and ran them through a specialized machine that acted like a sieve. This machine removed the alpha-beta T cells, which are the primary cells responsible for the dangerous immune attacks, and also removed B cells, which can sometimes cause other complications.

What remained in the bag of cells was a carefully curated mix. The filtered product still contained the stem cells needed to rebuild the patient's blood system, along with natural killer cells and a different type of T cell called gamma-delta T cells. These remaining cells are powerful against infections and cancer but are less likely to turn on the patient's body. The patients received a strong chemotherapy regimen to clear out their own marrow, and then they received this filtered donor infusion. Uniquely, because the dangerous cells had been removed beforehand, the patients did not need to take strong immunosuppressive drugs after the transplant to prevent rejection. This is a significant departure from standard practice, where patients must take heavy medications for months or years, leaving them vulnerable to infections.

The results of this approach were striking when viewed over the long term. The researchers followed the patients for a median of seven and a half years, a very long time in the world of cancer studies. In this group, not a single patient saw their Hodgkin lymphoma return. Every patient who received the transplant remained free of the disease. This is a remarkable outcome for a group of people who had failed multiple other treatments and were considered to have a very poor prognosis. The study also looked at the safety of the procedure. Two patients in the group passed away, but neither died from the cancer. One died from a severe viral infection that occurred because the donor and patient had a difficult combination of immune markers, a situation that modern antiviral drugs can now largely prevent. The other patient died from complications after receiving an extra dose of donor cells to boost their immune system, which unfortunately triggered an immune reaction. For the remaining eight patients, the transplant was successful, and they are living without the disease and without the need for long-term immunosuppressive drugs.

The immune system of these patients rebuilt itself in a predictable pattern. The cells that were preserved in the filter, such as the natural killer cells and gamma-delta T cells, returned to the patients' blood very quickly, often within the first few months. These cells acted as an early defense force against infections. The more complex immune cells, which are usually slower to return, eventually grew back as well, but the early presence of the innate defenders helped keep the patients safe during the most vulnerable period. The study noted that even patients who had received powerful immunotherapy drugs before the transplant did not suffer from the severe immune attacks that are sometimes seen when these drugs are used with standard transplants. This suggests that by removing the specific cells that cause the conflict, the doctors successfully separated the benefits of the new immune system from its risks.

While the number of patients in this study was small, and the research was conducted at a single center, the findings offer a compelling new direction for treating difficult cases of Hodgkin lymphoma. The approach demonstrates that it is possible to use a family donor, who is not a perfect match, without the high risk of life-threatening immune attacks that usually accompanies such a choice. By filtering the donor cells, the team created a transplant that is both potent against the cancer and gentle on the patient's body. The researchers acknowledge that this method requires specialized equipment and expertise, making it more complex than a standard transplant. However, for patients who have no other options and for whom the disease has returned, this strategy provides a path to a cure that was previously too dangerous to attempt. The success of this group, particularly the complete absence of cancer relapse over many years, suggests that this filtered transplant platform is a viable and powerful tool in the fight against Hodgkin lymphoma.